JEDDAH (TN Media News): Jamjoom Pharma, a leading Saudi pharmaceutical company, has entered into a strategic licensing and supply agreement with Althera Laboratories to introduce an advanced dyslipidemia therapy to Saudi Arabia and the broader Middle East and Africa (MEA) region.
This breakthrough partnership aims to provide effective solutions for managing high cholesterol, which contributes significantly to cardiovascular diseases in the region.
Exclusive Rights and Market Expansion
Under this agreement, Jamjoom Pharma secures exclusive rights to commercialize Althera’s fixed-dose, dual-action cholesterol-lowering therapy in Saudi Arabia. It also obtains non-exclusive rights for a phased rollout across other MEA markets.
The product launch in Saudi Arabia is planned for 2027, followed by gradual expansion to additional MEA countries, subject to local regulatory approvals. This step is expected to strengthen Jamjoom Pharma’s cardiovascular portfolio and make innovative therapies more accessible to patients.
Enhancing Cardiovascular Care in the MEA Region
Dr. Tarek Hosni, CEO of Jamjoom Pharma, emphasized the importance of this partnership:
“Cardiovascular diseases remain a leading health challenge in Saudi Arabia and MEA. This collaboration allows us to provide patients with an innovative, evidence-based solution. Our commitment is to improve lives with high-quality, affordable treatments.”
Sanjeev Agarwal, CEO of Althera, added:
“Partnering with Jamjoom Pharma is a pivotal step in extending our reach into a rapidly growing market. Jamjoom’s deep market knowledge and strong capabilities make them an ideal partner to deliver our therapy to healthcare providers and patients across MEA.”
Commitment to Better Patient Outcomes
The partnership reflects a joint mission to address the growing burden of cardiovascular disease by improving access to advanced lipid-lowering therapies. It supports patient care in line with Saudi Vision 2030, focusing on better health outcomes and increased treatment accessibility.
About Jamjoom Pharma
Jamjoom Pharma, established in 2000, is a leading Saudi pharmaceutical company dedicated to enhancing quality of life through the development and distribution of high-quality medicines and consumer healthcare products. The company serves diverse therapeutic areas, including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine, with operations across the MEA region.
About Althera Laboratories
Founded in 2010 and headquartered in Dublin, Ireland, Althera focuses on innovative therapies for heart disease, diabetes, and obesity. Its mission is to develop value-added combinations and affordable cardiovascular treatments that improve patient care worldwide.
